CHK1 inhibitor SRA737 is active in PARP inhibitor resistant and <i>CCNE1</i> amplified ovarian cancer.

iScience · 2024 · PMC11253285 · PMID 39021796

Europe PMC DOI

hedged sentences

—

closest p

—

boldest claim

The sentences

highly significantno p-value reported

32 In our study, a highly significant response to single agent SRA737 treatment was observed in an aggressive and platinum-refractory CCNE1 amp ovarian carcinosarcoma (OCS) PDX model.

also in 132,142 other papers

did not reach statistical significanceno p-value reported

Combination PARPi+SRA737 showed a trending increase in survival compared to SRA737 monotherapy, however, this did not reach statistical significance ( Table S2 ).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.